Management of disappearing colorectal hepatic metastases

Advances in Surgery

Volumn 44, Issue 1, 2010, Pages 269-279

  Carpenter, Susanne ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; COLORECTAL TUMOR; FATTY LIVER; HUMAN; LIVER TUMOR; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; REVIEW; SENSITIVITY AND SPECIFICITY; LIVER NEOPLASMS; SECONDARY;

CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FATTY LIVER; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, ADJUVANT; SENSITIVITY AND SPECIFICITY;

EID: 77956166838     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yasu.2010.05.001     Document Type: Review

References (38)

1. Nordlinger B., Parc R., Delva E., et al. Hepatic resection for colorectal liver metastases. Ann Surg 1987, 205:256-263.
2. Ewing H., Sali A., Kune G.A. Klatskin tumours: a 20 year experience. Aust N Z J Surg 1989, 59:25-30.
3. Butler J., Attiyeh F.F., Daly J.M. Hepatic resection for metastases of the colon and rectum. Surg Gynecol Obstet 1986, 162:109-113.
4. Morris K.T., Song T.J., Fong Y. Recent advancements in diagnosis and treatment of metastatic colorectal cancer to the liver. Surg Oncol 2006, 15:129-134.
5. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004, 240(4):644-657.
6. Silverberg E., Boring C.C., Squires T.S. Cancer statistics 1990. CA Cancer J Clin 1990, 40:9.
7. Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann Surg Oncol 2001, 8(4):347-353.
8. Ensminger W.D., Rosowsky A., Raso V., et al. A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluorouracil. Cancer Res 1978, 38(11):3784-3792.
9. Kemeny N.E., Huitzil Melendez F.D., Capanu M., et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009, 27:3465-3471.
10. Kemeny N., Jarnagin W., Paty P., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005, 23(22):4888-4896.
11. Kattan M.W., Karpeh M.S., Mazumdar M., et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003, 21(19):3647-3650.
12. Benoist S., Brouquet A., Penna C., et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 2006, 24(24):3939-3945.
13. Elias D., Youssef O., Sideris L., et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004, 86(1):4-9.
14. Fiorentini G., Del C.A., De S.M., et al. Complete response of colorectal liver metastases after intra-arterial chemotherapy. Tumori 2008, 94(4):489-492.
15. Auer RC, White RR, Kemeny NE, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010, 116(6):1502-1509.
16. Tan M.C., Linehan D.C., Hawkins W.G., et al. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007, 11(9):1112-1119.
17. Huebner R.H., Park K.C., Shepherd J.E., et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000, 41(7):1177-1189.
18. Bipat S., van Leewen M.S., Comans E.F., et al. Colorectal liver metastases: CT, MR imaging and PET for diagnosis-meta-analysis. Radiology 2005, 237(1):123-131.
19. Fong Y., Saldinger P.F., Akhurst T., et al. Utility of 18F-FDG-PET scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999, 178:282-287.
20. Kelloff G.J., Hoffman J.M., Johnson B., et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005, 11(8):2785-2808.
21. Akhurst T., Kates T.J., Mazumdar M., et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 2005, 23(34):8713-8716.
22. Peppercorn P.D., Reznek R.H., Wilson P., et al. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998, 77(11):2008-2011.
23. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24(13):2065-2072.
24. Zorzi D., Laurent A., Pawlik T.M., et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007, 94(3):274-286.
25. Valls C., Iannacconne R., Alba E., et al. Fat in the liver: diagnosis and characterization. Eur Radiol 2006, 16(10):2292-2308.
26. Oliva M.R., Mortele K.J., Segatto E., et al. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr 2006, 30(1):37-43.
27. Cho C.S., Curran S., Schwartz L.H., et al. Preoperative radiographic assessment of hepatic steatosis with histologic correlation. J Am Coll Surg 2008, 206(3):480-488.
28. Albrecht T., Blomley M.J., Burns P.N., et al. Improved detection of hepatic metastases with pulse-inversion US during the liver-specific phase of SHU 508A: multicenter study. Radiology 2003, 227(2):361-370.
29. Ward J., Robinson P.J., Guthrie J.A., et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology 2005, 237(1):170-180.
30. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999, 10(6):663-669.
31. Znajda T.L., Hayashi S., Horton P.J., et al. Postchemotherapy characteristics of hepatic colorectal metastases: remnants of uncertain malignant potential. J Gastrointest Surg 2006, 10(4):483-489.
32. Adam R., Wicherts D.A., de Haas R.J., et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?. J Clin Oncol 2008, 26(10):1635-1641.
33. Wong S.L., Mangu P.B., Choti M.A., et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2009, 28:493-508.
34. Pinkas L., Robins P.D., Forstrom L.A., et al. Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature. Nucl Med Commun 1999, 20(8):689-696.
35. Bismuth H., Adam R., Levi F., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996, 224(4):509-520.
36. Gallagher D.J., Capanu M., Raggio G., et al. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol 2007, 18(12):1995-1999.
37. Alberts S.R., Horvath W.L., Sternfeld W.C., et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005, 23(36):9243-9249.
38. Barone C., Nuzzo G., Cassano A., et al. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 2007, 97(8):1035-1039.